Clinical improvements at Week 36 sustained to Week 64 with aflibercept 8 mg in macular edema following retinal vein occlusion, with significantly fewer injections compared to aflibercept 2 mg: Results from the QUASAR trial

Ramin Khoramnia; Seenu M. Hariprasad; Varun Chaudhary; Youxin Chen; Andrew Chang; Motohiro Kamei; Sergio Leal; Tobias Niesen; Rose Gilbert; Anders Pryds; Sarah Schlief; Franco Mendolia; Zoran Hasanbasic; Alyson J. Berliner; Aditya Athanikar; Fabiana Q. Silva; Richard Gale

doi:10.3205/26doc135

June 17, 2026Open Access

Clinical improvements at Week 36 sustained to Week 64 with aflibercept 8 mg in macular edema following retinal vein occlusion, with significantly fewer injections compared to aflibercept 2 mg: Results from the QUASAR trial

View Full Paper

Ask AI

Bookmark

Share

Key Points

Evaluate the efficacy and safety of aflibercept 8 mg versus 2 mg in treatment-naïve macular edema following retinal vein occlusion.
Randomized double-masked controlled trial
64-week duration
NCT05850520 registered
Aflibercept 8 mg resulted in sustained clinical improvements at Week 64
Patients required significantly fewer injections compared to those treated with aflibercept 2 mg
Findings support the noninferiority of aflibercept 8 mg in treating macular edema.

Implication

Evaluates aflibercept 8 mg efficacy in macular edema, indicating fewer injections needed compared to 2 mg.

Abstract

Purpose: To evaluate the efficacy and safety of aflibercept 8 mg versus 2 mg in patients with treatment-naïve macular edema following retinal vein occlusion (MEfRVO). Methods: QUASAR (NCT05850520) was a 64-week, randomized, double-masked, active-controlled, noninferiority, Phase 3 trial of [for full text, please go to the a.m. URL]

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

Khoramnia et al. (2026) studied this question.

synapsesocial.com/papers/6a34de4165a5b0777af2db06 https://doi.org/10.3205/26doc135

View Full Paper

Ask AI

Bookmark

Share

Clinical improvements at Week 36 sustained to Week 64 with aflibercept 8 mg in macular edema following retinal vein occlusion, with significantly fewer injections compared to aflibercept 2 mg: Results from the QUASAR trial

Key Points

Implication

Abstract

Discussion

Cite This Study

Clinical improvements at Week 36 sustained to Week 64 with aflibercept 8 mg in macular edema following retinal vein occlusion, with significantly fewer injections compared to aflibercept 2 mg: Results from the QUASAR trial

Key Points

Implication

Abstract

Discussion

Cite This Study

Keep reading

Keep reading